Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2011 Dec 1.

Published in final edited form as: Am J Obstet Gynecol. 2010 Sep 25;203(6):582.e1–582.e7. doi: 10.1016/j.ajog.2010.07.041

Representative cytotoxicity experiments adding human serum to MT201 against OSPC-ARK-1 (upper panel), CC-ARK-1 (middle panel) and CC-ARK-2 (lower panel) cell lines. Ovarian cancer cell lines were challenged by diluted (1:2) serum (with or without heat inactivation) in the presence or absence of the effector cells and MT201 to standard 4-h ⁵¹Cr release assays. Addition of physiological concentrations of IgG (i.e., heat-inactivated serum diluted 1:2) to PBL in the presence of MT201 significantly reduced the degree of ADCC achieved in the presence of MT201 against OSPC-ARK-1 and CC-ARK-1. Addition of untreated serum (diluted 1:2) to PBL in the presence of MT201 consistently increased MT201-mediated cytotoxicity against and CC-ARK-1 (p < 0.03) (lower panel).

Representative cytotoxicity experiments adding human serum to MT201 against OSPC-ARK-1 (upper panel), CC-ARK-1 (middle panel) and CC-ARK-2 (lower panel) cell lines. Ovarian cancer cell lines were challenged by diluted (1:2) serum (with or without heat inactivation) in the presence or absence of the effector cells and MT201 to standard 4-h ⁵¹Cr release assays. Addition of physiological concentrations of IgG (i.e., heat-inactivated serum diluted 1:2) to PBL in the presence of MT201 significantly reduced the degree of ADCC achieved in the presence of MT201 against OSPC-ARK-1 and CC-ARK-1. Addition of untreated serum (diluted 1:2) to PBL in the presence of MT201 consistently increased MT201-mediated cytotoxicity against and CC-ARK-1 (p < 0.03) (lower panel).